[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334484-105":59,"doc-detail-334484-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-effects-of-oxaliplatin-based-adjuvant-chemotherapy-in-high-risk-stage-ii-colon-cancer-with-mismatch-repair-deficient-a-retrospective-study","The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study","","Adjuvant chemotherapy benefits for high-risk stage II mismatch repair-deficient (dMMR) colon cancer remain uncertain. This retrospective study evaluated prognostic value of high-risk factors and the effect of oxaliplatin-based adjuvant chemotherapy among dMMR stage II colon cancers. Patients diagnosed from June 2011 to May 2018 were classified into high- and low-risk groups by factors including pT4, \u003C12 lymph nodes, poor differentiation, perineural invasion, lymphatic vascular invasion, and elevated preoperative CEA.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-effects-of-oxaliplatin-based-adjuvant-chemotherapy-in-high-risk-stage-ii-colon-cancer-with-mismatch-repair-deficient-a-retrospective-study/334484/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-effects-of-oxaliplatin-based-adjuvant-chemotherapy-in-high-risk-stage-ii-colon-cancer-with-mismatch-repair-deficient-a-retrospective-study/334484.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which high-risk factors defined the high-risk group in dMMR stage II colon cancer?","Question",{"text":112,"@type":113},"The high-risk group included pT4 disease, fewer than 12 lymph nodes harvested, poorly differentiated histology, perineural invasion, lymphatic vascular invasion, and elevated preoperative CEA. Patients without any of these factors were classified as low-risk.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What were the main findings on disease-free survival (DFS) by risk group?",{"text":117,"@type":113},"Among 262 patients, 179 had at least one high-risk factor. With a median follow-up of 50.1 months, the low-risk group showed a tendency toward better 3-year DFS than the high-risk group (96.4% vs 89.4%).",{"name":119,"@type":110,"acceptedAnswer":120},"Did oxaliplatin-based adjuvant chemotherapy improve outcomes in high-risk dMMR stage II patients?",{"text":121,"@type":113},"No survival benefit from oxaliplatin-based adjuvant chemotherapy was observed in the high-risk group, nor in subgroups with pT4 disease or fewer than 12 lymph nodes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334484,1790192732,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Liao et al. BMC Cancer (2024) 24:164  \n[https://doi.org/10.1186/s12885-024-11821-w](https://doi.org/10.1186/s12885-024-11821-w)  \nBMC Cancer  \n RESEARCH Open Access  \nThe effects of oxaliplatin-based adjuvant  \nchemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study  \nLeen Liao1,2†, Jinghua Tang1,2†, Zhigang Hong1,2†, Wu Jiang1,2, Yuan Li1,2, Lingheng Kong1,2, Kai Han 1,2, Zhenlin Hou1,2, Chenzhi Zhang1,2, Chi Zhou1,2, Linjie Zhang1,2, Qiaoqi Sui1,2, Binyi Xiao1,2, Weijian Mei 1,2, Jiehai Yu1,2, Wanjun Yang1,2, Zhizhong Pan1,2* and Pei‑Rong Ding 1,2*  \nAbstract  \nBackground For high‑risk stageIImismatch repair deficient (dMMR) colon cancers, the benefit of adjuvant chemo‑ therapy remains debatable. The principal aim of this study was to evaluate the prognostic value of high‑risk factors and the effect of oxaliplatin‑based adjuvant chemotherapy among dMMR stageIIcolon cancers.  \nMethods Patients with stage II dMMR colon cancers diagnosed between June 2011 and May 2018 were enrolled in the study. Clinicopathological characteristics, treatment, and follow‑up data were retrospectively collected. The high‑risk group was defined as having one of the following factors: pT4 disease, fewer than twelve lymph nodes har‑ vested (\u003C 12 LNs), poorly differentiated histology, perineural invasion (PNI), lymphatic vascular invasion (LVI), or ele‑ vated preoperative carcinoembryonic antigen (CEA) . The low‑risk group did not have any risk factors above. Factors associated with disease‑free survival (DFS) were included in univariate and multivariate Cox analyses.  \nResults We collected a total of 262 consecutive patients with stage II dMMR colon cancer. 179 patients (68 . 3%) have at least one high‑risk factor. With a median follow‑up of 50.1 months, the low‑risk group was associated with a tended to have a better 3‑year DFS than the high‑risk group (96 .4% vs 89 .4%; P = 0 . 056) . Both elevated preoperative CEA (HR 2. 93; 95% CI 1.26–6. 82; P = 0 . 013) and pT4 disease (HR 2 . 58; 95% CI 1.06–6. 25; P = 0 . 037) were independent risk factors of recurrence. Then, the 3‑year DFS was 92. 6% for the surgery alone group and 88. 1% for the adjuvant chemotherapy group (HR 1. 64; 95% CI 0.67–4. 02; P = 0 . 280) . Furthermore, no survival benefit from oxaliplatin‑based adjuvant chemo‑ therapy was observed in the high‑risk group and in the subgroups with pT4 disease or \u003C 12 LNs.  \nConclusions These data suggests that not all high‑risk factors have a similar impact on stage II dMMR colon cancers. Elevated preoperative CEA and pT4 tumor stage are associated with increased recurrence risk. However, oxaliplatin‑ based adjuvant chemotherapy shows no survival benefits in stage II dMMR colon cancers, either with or with‑ out high‑risk factors.  \n†Leen Liao, Jinghua Tang, Zhigang Hong contributed equally to this work.  \n*Correspondence: Zhizhong Pan [panzhzh@sysucc.org.cn](panzhzh@sysucc.org.cn)[ ](panzhzh@sysucc.org.cn)Pei‑Rong Ding [dingpr@sysucc.org.cn](dingpr@sysucc.org.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://c","cbCail6ARanq4MTM","https://ap.wps.com/l/cbCail6ARanq4MTM","pdf",1072160,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n## Keywords\n## Background (study rationale)","[{\"question\":\"Which high-risk factors defined the high-risk group in dMMR stage II colon cancer?\",\"answer\":\"The high-risk group included pT4 disease, fewer than 12 lymph nodes harvested, poorly differentiated histology, perineural invasion, lymphatic vascular invasion, and elevated preoperative CEA. Patients without any of these factors were classified as low-risk.\"},{\"question\":\"What were the main findings on disease-free survival (DFS) by risk group?\",\"answer\":\"Among 262 patients, 179 had at least one high-risk factor. With a median follow-up of 50.1 months, the low-risk group showed a tendency toward better 3-year DFS than the high-risk group (96.4% vs 89.4%).\"},{\"question\":\"Did oxaliplatin-based adjuvant chemotherapy improve outcomes in high-risk dMMR stage II patients?\",\"answer\":\"No survival benefit from oxaliplatin-based adjuvant chemotherapy was observed in the high-risk group, nor in subgroups with pT4 disease or fewer than 12 lymph nodes.\"}]","The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study | PDF",1790006825,23]